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Abstract
Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly
linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in
patients with renal insufficiency. This review discusses recent advances in our understanding of the
pathophysiology and clinical approach to patients with chronic kidney disease who require diagnostic
imaging with gadolinium-based contrast media.
Introduction and context
Nephrogenic systemic fibrosis (NSF), initially named
nephrogenic fibrosing dermopathy, was first reported in
2001 by Cowper et al. [1]. The earliest known case of NSF
developed in January 1997. Since then, more than 360
cases have been tracked by the Yale International NSF
Registry [2] and over 500 cases have been reported to the
US Food and Drug Administration MedWatch database.
NSF occurs most often in middle-aged adults (mean age
of 52 years) with either chronic kidney disease or acute
kidney injury but has also been observed in children
and older patients. NSF usually manifests approximately
2-10 weeks (median 5 weeks) after exposure to
gadolinium-based contrast agents (GBCAs). There is no
gender or racial predisposition.
Of NSF cases reported to the Yale Registry, all have
occurred in patients with renal insufficiency. In recent
years it has become clear that NSF is also associated with
fibrotic damage to internal viscera such as the esophagus,
lungs, heart, skeletal muscle, and kidneys (prompting a
change in name from nephrogenic fibrosing dermopathy
to nephrogenic systemic fibrosis). In some cases NSF
has contributed to the death of the afflicted individual.
By 2007, it became apparent that the common factor
in most patients was the prior use of GBCAs during
magnetic resonance imaging, however, in many cases
(e.g., when imaging brain tumors), the use of GBCAs are
critical for enhancing the imaging of blood vessels.
ThebasicclinicalfeaturesofNSFincludeacutetosubacute
onset of limb edema (more so in the lower limbs) accom-
panied by cutaneous erythematous to violaceous papules
and plaques overlying dermal and subcutaneous fat
fibrosis. When fully developed, clinical NSF is character-
ized by limb pain, contractures, and loss of mobility. The
clinical syndrome strongly mimics scleroderma and
eosinophilic fasciitis, and may be rapidly progressive.
Yellow scleral plaques mimicking pingueculae are often
present in affected patients.
NSF has specific clinical and histopathologic characte-
r i s t i c st h a ts h o u l db eu s e dt om a k ead e f i n i t i v e
diagnosis. Histologic features include a haphazard
arrangement of thickened collagen bundles, mucin
deposition, and an increase in fibroblast-like cells that
stain positively for CD34 and procollagen I, the same
immunohistochemical profile as that of ‘circulating
fibrocytes’ (which play an important role in disease
development). This abnormal pathology extends into
the fibrous septa between fat lobules, contributing to
the typical clinical manifestation of woody indura-
tion and a ‘peau d’orange’ or ‘cobblestone’ skin surface
appearance. It has been hypothesized that this
pathology is the effect of the bone marrow-derived
circulating fibrocytes (normally recruited to repair
injured tissue) behaving in an exuberantly abnormal
fashion in the dermis and fibrous septa of the
subcutaneous fat.
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To date, the Yale Registry indicates that at the time of
disease onset, 79% of patients with NSF were receiving
renal dialysis and 17% had some degree of renal
insufficiency but were not being dialyzed (those with
acute kidney injury, unspecified renal insufficiency, or
chronic kidney disease stage IV or V). The remaining
patients were in the immediate post-renal-transplant
period (Cowper, unpublished data).
Experimental data suggests that when gadolinium, a rare
earth element that is naturally highly toxic to animals
and humans, is bound to proprietary chelating agents, it
is essentially biologically inert in the circulation of a
patient with normal kidney function (in whom the half-
life would be roughly 90 minutes) [3]. Since GBCAs are
cleared from the body virtually exclusively by the
kidneys, the current hypothesis is that individuals with
reduced renal clearance are exposed to these agents
longer than those with normal renal function, which can
lead to NSF in the vulnerable, however, the exact
pathogenic mechanisms remain unknown.
Because gadolinium is not normally ingested by humans,
radiologic examinations where GBCAs are administered
are the only significant source of human exposure. Several
pharmaceutical companies produce a variety of GBCAs,
which are distinguishable by their varying proprietary
chelating agents (ligands). The ligands are classified as
structurally linear or macrocyclic and exhibit both
ionic and non-ionic forms. The macrocyclic gadolinium-
ligand complexes are less prone to ‘dechelation’ (which
would render the GBCA potentially toxic) and are
therefore more stable than the linear non-ionic agents.
This is thought to be the underlying reason why
macrocyclic agents are only rarely associated with NSF.
Interestingly, even among the linear agents there may be
differences in propensity to trigger NSF between ionic
and non-ionic varieties.
In the event of dechelation, ionic gadolinium (Gd
3+)
quickly binds to ubiquitous phosphate, forming inso-
luble gadolinium phosphate and leading to prolonged
exposure to biologically active gadolinium. With gado-
linium no longer circulating, it cannot be significantly
removed by dialysis. Complicating the situation is that,
over the years, various GBCAs have been used inter-
changeably and patients’ charts typically do not necessa-
rily reflect which brands were administered, making it
very difficult to retrospectively pinpoint the precise
agents used. The risk of NSF is estimated to be between
2% and 6% in patients with chronic kidney disease
(stage IV and V) and acute kidney injury, with the
most risk associated with higher degrees of impairment
and less effective modes of clearance (i.e., peritoneal
dialysis) [3].
A recent change in FDA labeling of GBCAs suggests the
linear non-ionic agents (OptiMARK and Omniscan) as
well as the most widely-used linear ionic agent (Magne-
vist) be specifically contraindicated in the setting of renal
disease. The warning requires that screening (medical
history and/or laboratory tests) be conducted for renal
dysfunction prior to the administration of GBCAs [4].
These recent labeling changes are in line with recom-
mendations already made by the European Medicines
Agency and the American College of Radiology. Since the
FDA black box warnings were first issued in 2007, the
incidence of new cases has dropped from 36.5 cases per
100,000 to 4 cases per 100,000 [5].
In general, treatment of NSF using topical steroids,
immunosuppressive therapy, and plasmapheresis has
been ineffective.Several studies have described anecdotal
treatments that may improve NSF, including ultraviolet-
A exposure, pentoxifylline, sodium thiosulfate, photo-
pheresis, and rapamycin, however, these studies suffered
from small numbers, no controls, and sometimes a lack
of peer review. Recent data presented by Jonathan Kay
[6] at the Fourth Annual Symposium on Nephrogenic
Systemic Fibrosis and Gadolinium-based Contrast
Agents demonstrated that imatinib mesylate improved
skin tethering and thickening as judged by the Rodnan
skin score. However, all of the patients in the study
relapsed after the drug was discontinued and it has not
yet been determined whether the noted beneficial effects
were related to a reduction in interstitial edema or a
partial reversal of the fibrosis. The second-generation
drugs dasatinib and nilotinib are currently in the queue
to be evaluated.
High et al. [7] at the University of Colorado used energy
dispersive spectroscopy, X-ray microscopy, and induc-
tively coupled plasma mass spectroscopy to detect
gadolinium in skin and other tissues from patients
with NSF. However, based on their studies, a high tissue
level of gadolinium is not necessarily sufficient to
produce NSF by itself. They also showed that gadolinium
could be displaced (‘dechelated’) from its ligand in the
presence of another metal such as iron or zinc. This
‘transmetallation’ would result in free ionic gadolinium
(which, as noted above, would be very likely to form
insoluble gadolinium phosphate) and a ligand complex
with iron, zinc, or another displacing metal. Factors
which facilitate transmetallation are high or low blood
pH levels, endothelial injury, inflammation, and high
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milieu of patients with renal insufficiency [8]. High et al.
[7] also showed that the tissues with the highest levels of
gadolinium are associated with the most severe fibrosis
in the skin and other organs such as the heart, lungs,
lymph nodes, eye tissues, muscle, and liver. Synchrotron
X-ray fluoroscopy also has been used successfully to
detect gadolinium in tissues [8].
Basic science
NSF is the only fibrosing disorder where the trigger is
essentially known but the pathogenic mechanisms have
yet to be fully clarified. NSF can also serve as a model to
gain an understanding of the pathways responsible for
idiopathic fibrosing disorders in other organ systems.
Current investigation into NSF has revealed that in vitro
GBCAs stimulate fibroblasts from patients with NSF
(and those from normal controls) to secrete increased
amounts of extracellular matrix, hyaluronic acid, and
collagen. However, serum from patients with NSF also
stimulates fibroblasts to secrete increased amounts of
these same substances. Serum from dialysis patients
behaves similarly but not to the same magnitude. In rats,
some linear GBCAs stimulate fibroblasts to proliferate
and caused normal fibroblasts to transform into
myofibroblast-like cells with a phenotype similar to
that of differentiated fibroblasts present in NSF lesions.
Chelating agents alone (sans gadolinium) did not
produce these effects. Therefore, free gadolinium is the
most obvious suspect in promoting NSF [9,10].
Fibrocytes, circulating bone marrow-derived mesenchy-
mal stem cells, also accumulate in NSF lesions, where
they further differentiate into fibroblasts and myofibro-
blasts. Increased sensitivity of NSF fibrocytes to gadoli-
nium has been shown in various experiments [11,12].
In another rat model, gadolinium produced skin lesions
but the chelating agents did not. It is clear that the
stability of the GBCA complex is the most important
factor, thereby implicating free gadolinium as the culprit
in inducing the disease and absolving the chelating
agents [13]. In studies of renally insufficient rats, linear
non-ionic GBCAs produced the most gadolinium
deposition in the skin, which was further promoted by
high tissue levels of phosphate [14].
Animal models have provided further evidence for the
role of other molecules in NSF. The first is osteopontin, a
multifunctional protein first identified in bone but
present in virtually all tissues. A major modulator of
processes involving fibrosis and wound repair, osteo-
pontin was found to be elevated in an experimental
gadolinium-induced rat model of NSF [15]. Additonally,
Cox [16] created a gadolinium-induced rat model of NSF
in which an experimental anti-platelet-derived growth
factor receptor compound, as well as the cancer drug
imatinib, were both effective in preventing and reversing
fibrosis.
Implications for clinical practice
Recent reports have indicated that patients at the highest
risk for NSF have chronic kidney disease stages IV or V
and that no cases have been observed in patients in
earlier stages thus far [17,18]. Similarly, patients with
acute kidney injury appear to be susceptible to NSF.
Therefore, careful screening of patients for underlying
kidney disease or severe injury using measurements of
serum creatinine and other appropriate tests of renal
function (the choice of which depends on medical
history and physical examination) should decrease the
risk of NSF in patients receiving GBCAs. Keeping a
careful history of previous exposure to a GBCA, both in
time and dose, would assist in GBCA selection and in
calculating an appropriate dose to be administered. Post-
imaging dialysis has also been proposed as a way to
mitigate the development of NSF in certain high-risk
patients by removing circulating GBCA in a more timely
manner. Currently, this is recommended only in cases in
which the patient is already receiving hemodialysis. For
those not being dialyzed, or those on peritoneal dialysis,
no specific recommendations exist.
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